New hope for Tough-to-Treat blood cancer
Disease control
Recruiting now
This study is testing how safe and effective a combination of two new drugs, mezigdomide and elranatamab, is for people with multiple myeloma that has come back or stopped responding to other treatments. The first part of the study will find the best dose, and the second part wil…
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC